Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871

Detalles Bibliográficos
Autores principales: Rodriguez, Emma, Pei, Guangsheng, Zhao, Zhongming, Kim, Sang T., German, Alexis, Robinson, Prema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Erratum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533910/
https://www.ncbi.nlm.nih.gov/pubmed/34680400
http://dx.doi.org/10.3390/cancers13205178
_version_ 1784587427682189312
author Rodriguez, Emma
Pei, Guangsheng
Zhao, Zhongming
Kim, Sang T.
German, Alexis
Robinson, Prema
author_facet Rodriguez, Emma
Pei, Guangsheng
Zhao, Zhongming
Kim, Sang T.
German, Alexis
Robinson, Prema
author_sort Rodriguez, Emma
collection PubMed
description
format Online
Article
Text
id pubmed-8533910
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85339102021-10-23 Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871 Rodriguez, Emma Pei, Guangsheng Zhao, Zhongming Kim, Sang T. German, Alexis Robinson, Prema Cancers (Basel) Erratum MDPI 2021-10-15 /pmc/articles/PMC8533910/ /pubmed/34680400 http://dx.doi.org/10.3390/cancers13205178 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Erratum
Rodriguez, Emma
Pei, Guangsheng
Zhao, Zhongming
Kim, Sang T.
German, Alexis
Robinson, Prema
Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871
title Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871
title_full Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871
title_fullStr Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871
title_full_unstemmed Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871
title_short Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871
title_sort erratum: rodriguez et al. substance p antagonism as a novel therapeutic option to enhance efficacy of cisplatin in triple negative breast cancer and protect pc12 cells against cisplatin-induced oxidative stress and apoptosis. cancers 2021, 13, 3871
topic Erratum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533910/
https://www.ncbi.nlm.nih.gov/pubmed/34680400
http://dx.doi.org/10.3390/cancers13205178
work_keys_str_mv AT rodriguezemma erratumrodriguezetalsubstancepantagonismasanoveltherapeuticoptiontoenhanceefficacyofcisplatinintriplenegativebreastcancerandprotectpc12cellsagainstcisplatininducedoxidativestressandapoptosiscancers2021133871
AT peiguangsheng erratumrodriguezetalsubstancepantagonismasanoveltherapeuticoptiontoenhanceefficacyofcisplatinintriplenegativebreastcancerandprotectpc12cellsagainstcisplatininducedoxidativestressandapoptosiscancers2021133871
AT zhaozhongming erratumrodriguezetalsubstancepantagonismasanoveltherapeuticoptiontoenhanceefficacyofcisplatinintriplenegativebreastcancerandprotectpc12cellsagainstcisplatininducedoxidativestressandapoptosiscancers2021133871
AT kimsangt erratumrodriguezetalsubstancepantagonismasanoveltherapeuticoptiontoenhanceefficacyofcisplatinintriplenegativebreastcancerandprotectpc12cellsagainstcisplatininducedoxidativestressandapoptosiscancers2021133871
AT germanalexis erratumrodriguezetalsubstancepantagonismasanoveltherapeuticoptiontoenhanceefficacyofcisplatinintriplenegativebreastcancerandprotectpc12cellsagainstcisplatininducedoxidativestressandapoptosiscancers2021133871
AT robinsonprema erratumrodriguezetalsubstancepantagonismasanoveltherapeuticoptiontoenhanceefficacyofcisplatinintriplenegativebreastcancerandprotectpc12cellsagainstcisplatininducedoxidativestressandapoptosiscancers2021133871

Ejemplares similares